The West Nile Virus Infections drugs in development market research report provides comprehensive information on the therapeutics under development for West Nile Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for West Nile Virus Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued products.
GlobalData tracks 19 drugs in development for West Nile Virus Infections by 17 companies/universities/institutes. The top development phase for West Nile Virus Infections is preclinical with eight drugs in that stage. The West Nile Virus Infections pipeline has ten drugs in development by companies and nine by universities/ institutes. Some of the companies in the West Nile Virus Infections pipeline products market are: Plex Pharmaceuticals, Imutex and Bugworks Research.
The key targets in the West Nile Virus Infections pipeline products market include P27 (Negative Regulatory Factor or Nef), Nonstructural Protein 5 (NS5), and mRNA Guanylyltransferase (EC 2.7.7.50).
The key mechanisms of action in the West Nile Virus Infections pipeline product include Nonstructural Protein 5 (NS5) Inhibitor with one drug in Discovery. The West Nile Virus Infections pipeline products include six routes of administration with the top ROA being Oral and eight key molecule types in the West Nile Virus Infections pipeline products market including Small Molecule, and Vaccine.
West Nile Virus Infections overview
West Nile infection is caused by a virus transmitted by mosquitoes. The West Nile virus is a type of virus known as a Flavivirus. Symptoms include a fever, headache, body aches, skin rash, and swollen lymph glands. Risk factors for developing a more severe form of West Nile virus include conditions that weaken the immune system, such as HIV, organ transplants, and recent chemotherapy, and age and pregnancy.
For a complete picture of West Nile Virus Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
